Actinic keratosis Pipeline Summary

DelveInsight’s, “Actinic keratosis - Pipeline Insight, 2026” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Actinic keratosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Actinic keratosis: Understanding

Actinic keratosis: Overview

Actinic keratosis (AK) is a common premalignant skin lesion caused by chronic exposure to ultraviolet (UV) radiation. It is characterized by rough, scaly patches that develop primarily on sun-exposed areas such as the face, scalp, ears, forearms, and hands. Although most lesions remain benign, a proportion may progress to cutaneous squamous cell carcinoma, making early diagnosis and treatment essential. The primary cause of actinic keratosis is prolonged cumulative exposure to ultraviolet (UV) radiation, particularly UVB rays, which induce DNA damage in epidermal keratinocytes. Other risk factors include fair skin, increasing age, male sex, immunosuppression, outdoor occupations, a history of frequent sunburns, and genetic conditions associated with UV sensitivity. These factors increase the likelihood of developing multiple AK lesions over time.

Actinic keratosis develops as a result of repeated UV-induced DNA damage, leading to mutations in key tumor suppressor genes, particularly TP53, and impaired DNA repair mechanisms. These molecular alterations promote abnormal proliferation and dysplasia of epidermal keratinocytes while preventing normal apoptosis. Chronic UV exposure also induces local immunosuppression and persistent inflammation, facilitating the accumulation of atypical keratinocytes that may progress to invasive cutaneous squamous cell carcinoma if left untreated.

Diagnosis of actinic keratosis is primarily based on a thorough clinical examination, considering the patient's history of chronic sun exposure and the characteristic appearance of rough, scaly, erythematous, or hyperkeratotic papules and plaques on sun-exposed areas of the skin. Dermoscopy serves as a valuable non-invasive diagnostic tool by revealing characteristic features, such as a strawberry-like pseudonetwork, keratin scales, and specific vascular patterns, thereby improving diagnostic accuracy and distinguishing AK from other skin lesions. A skin biopsy is recommended for suspicious or atypical lesions to confirm the diagnosis and rule out invasive cutaneous squamous cell carcinoma.

Treatment aims to eradicate visible lesions, manage the surrounding field of cancerization, and reduce the risk of progression to squamous cell carcinoma. Common lesion-directed therapies include cryotherapy, curettage, and surgical excision, while field-directed treatments include topical 5-fluorouracil, imiquimod, diclofenac, tirbanibulin, and photodynamic therapy. Preventive measures such as regular sun protection and routine skin surveillance are essential to minimize recurrence and the development of new lesions.

"Actinic keratosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Actinic keratosis pipeline landscape is provided which includes the disease overview and Actinic keratosis treatment guidelines. The assessment part of the report embraces, in depth Actinic keratosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Actinic keratosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Actinic keratosis R&D. The therapies under development are focused on novel approaches to treat/improve Actinic keratosis.

Actinic keratosis Emerging Drugs Chapters

This segment of the Actinic keratosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Actinic keratosis Emerging Drugs

• VDA-1102: Vidac Pharma

VDA-1102 is a first-in-class topical ointment being developed by Vidac Pharma. The drug selectively targets abnormal cells by disrupting cancer cell metabolism, inducing apoptosis while sparing healthy surrounding tissue. In addition to its direct anti-proliferative activity, VDA-1102 may reduce the immunosuppressive tumor microenvironment and enhance anti-tumor immune responses. Clinical studies have demonstrated favorable safety, tolerability, and promising efficacy, supporting its continued development. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Actinic keratosis.

Further product details are provided in the report……..

Actinic keratosis: Therapeutic Assessment

This segment of the report provides insights about the different Actinic keratosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Actinic keratosis

There are approx. 6+ key companies which are developing the therapies Actinic keratosis. The companies which have their Actinic keratosis drug candidates in the most advanced stage, i.e. Phase II include, Vidac Pharma and others.

• Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Actinic keratosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Actinic keratosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Actinic keratosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Actinic keratosis drugs.

Actinic keratosis Report Insights

• Actinic keratosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Actinic keratosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Actinic keratosis drugs?
• How many Actinic keratosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Actinic keratosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Actinic keratosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Actinic keratosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vidac Pharma
• Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Key Products

• VDA-1102
• HW 211026